Breztri Aerosphere is a prescription inhaler used for the ongoing, daily management of chronic obstructive pulmonary disease (COPD). It combines three active medications into a single inhaler, making it what’s known as a “triple therapy” option for people whose COPD isn’t well controlled with fewer medications. It is not approved for treating asthma and should not be used as a rescue inhaler during sudden breathing emergencies.
What Breztri Treats
Breztri is specifically approved for maintenance treatment of COPD, an umbrella term that includes chronic bronchitis and emphysema. “Maintenance” means it’s designed for daily, scheduled use to keep symptoms under control over time. It won’t provide fast relief during an acute flare-up or sudden shortness of breath. You still need a separate rescue inhaler for those moments.
Breztri is typically prescribed when a person’s COPD symptoms, particularly flare-ups (called exacerbations), aren’t adequately managed by one or two inhaled medications alone. In a large clinical trial known as ETHOS, patients using Breztri’s triple combination experienced roughly 1.25 moderate-to-severe exacerbations per year, compared to 1.63 per year for those using a two-drug combination of a long-acting muscarinic antagonist and a long-acting bronchodilator. That’s a meaningful reduction for people who deal with frequent flare-ups that can lead to emergency visits or hospitalizations.
How the Three Ingredients Work Together
Breztri packs three different types of medication into one inhaler, each targeting a different aspect of COPD:
- An inhaled corticosteroid (budesonide) reduces inflammation inside the airways. Chronic inflammation is a major driver of COPD symptoms and flare-ups, so this component works to calm the ongoing irritation in the lungs.
- A long-acting muscarinic antagonist (glycopyrrolate) blocks signals that cause airway muscles to tighten. This keeps the airways relaxed and open for extended periods.
- A long-acting beta2-agonist (formoterol fumarate) also relaxes airway muscles, but through a different pathway. It works relatively quickly compared to the other long-acting component and provides sustained bronchodilation throughout the day.
The two bronchodilators open the airways through complementary mechanisms, while the corticosteroid addresses the underlying inflammation. Combining all three into one device simplifies daily treatment and can improve adherence compared to juggling multiple inhalers.
How Breztri Is Used
The standard dose is two puffs twice a day: two in the morning and two in the evening. You should not exceed that amount. Because it’s a metered-dose inhaler (the pressurized canister type), using proper technique matters. Coordinating the press of the canister with a slow, deep breath helps ensure the medication reaches deep into the lungs where it’s needed.
Rinsing your mouth with water after each use is a good habit with any inhaler containing a corticosteroid. This helps prevent oral thrush, a fungal infection that can develop when steroid residue sits in the mouth and throat.
Who Should Not Use Breztri
Breztri carries two important limitations. First, it is not indicated for asthma. Long-acting bronchodilators like the one in Breztri have been associated with increased risk of serious complications when used in asthma patients without an appropriate corticosteroid regimen, so the FDA drew a clear line. Second, it should never be used as a rescue medication during sudden breathing difficulty. It takes time to work and is designed for prevention, not rapid relief.
People with a known allergy to any of the three active ingredients, or to the inactive components of the inhaler, should not use it. Certain medical conditions, including uncontrolled cardiovascular problems, seizure disorders, thyroid disorders, and narrow-angle glaucoma, may require extra caution because the bronchodilator components can affect heart rate and other body systems. Urinary retention issues can also be worsened by the anticholinergic ingredient, which relaxes smooth muscle beyond just the airways.
Common Side Effects
The most frequently reported side effects in clinical trials were upper respiratory tract infections, thrush in the mouth or throat, and headache. Some people also experience back pain, muscle spasms, or a hoarse voice. These are generally consistent with the known profiles of inhaled corticosteroids and long-acting bronchodilators, and most are mild to moderate.
Less common but more serious risks include pneumonia (a recognized concern with inhaled corticosteroids in COPD patients), worsening of narrow-angle glaucoma, urinary retention, and cardiovascular effects like increased heart rate or changes in heart rhythm. Bone density loss is another long-term consideration with sustained corticosteroid use, though the inhaled route delivers far lower systemic doses than oral steroids.
Where Breztri Fits in COPD Treatment
COPD treatment generally follows a stepwise approach. Many people start with a single long-acting bronchodilator, then move to a combination of two medications if symptoms persist. Breztri represents the next step: triple therapy for patients who continue to have exacerbations or poorly controlled symptoms despite dual therapy. It’s not a first-line treatment for someone newly diagnosed with mild COPD.
The convenience of having all three medications in one inhaler is a practical advantage. Managing multiple inhalers with different dosing schedules is a common source of confusion, and simplifying the regimen can help people use their medications consistently. For patients who’ve been using two separate inhalers to get the same combination of drug classes, switching to Breztri consolidates that into a single device with a straightforward twice-daily schedule.